Fact CheckerSign in

NCT07747935Not yet recruitingPhase 1/2

Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma

A Phase 1b, Open-Label, Investigator-Led Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma

Source: ClinicalTrials.gov · Last updated 5 Aug 2026

Brief summary (registry, in English)

Neoadjuvant RBP-01 in patients with primary uveal melanoma.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
30 (estimated)
First submitted
30 Jul 2026
Start date
1 Oct 2026
Primary completion date
1 Apr 2028
Lead sponsor
ReBio Pharma
Diseases
Melanoma
NCT number
NCT07747935

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 30
  • From 1 Oct 2026 to the primary completion date, 1 Apr 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participant has received previous treatment with a PKC inhibitor at any time.
  • Participant has received a prior diagnosis of metastatic disease.

Other illness

  • Participant is under active treatment for any other macular condition.
    • 9\. Female participants who are pregnant or lactating. 10. Participant is unable to follow protocol requirements.

Other

  • Presence of a tumour originating from the iris.
  • Presence of intractable untreatable raised intraocular pressure.
  • Presence of ring melanoma.
  • Presence of severe glaucoma or uveitis.

Who the study is looking for

  • Male and female participants aged ≥18 years.
  • Participants with choroidal and ciliary body \[P13.1\] tumours.
  • Participants with primary localized UM requiring enucleation (Cohort 1) or plaque brachytherapy at high risk of vision loss (Cohort 2), as per investigator assessment.
  • Participants with ECOG performance status 0-1.
  • Tumour thickness \> 4 mm.
  • Females of child bearing potential must have a negative urine pregnancy test result at screening.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.